Citations

Showing 10 of 108083 citations.

Instructional Strategies and Student eTextbook Reading
Russell, J. M. , Smith, Anna Marie , George, Salim , Damman, Bryce , Damman, Bryce

Mayo Clinic

LAK23: 13th International Learning Analytics and Knowledge Conference | February 21, 2023 | Volume: No volume available | Issue: No issue available | Pages: 613-618

10.1145/3576050.3576086 Get It

In Response: Women Leadership in Liver Transplantation
Pai, Sher‐Lu , Selzner, Nazia

Mayo Clinic

Transplantation | February 21, 2023 | Volume: 107 | Issue: 3 | Pages: e85-e85

10.1097/tp.0000000000004495 | PMID 36808853 Get It

An Uncommon Cause of Severe Polyradiculopathy
Grill, Marie , Gupta, Simran

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | February 21, 2023 | Volume: 2 | Issue: 2 | Pages: No page available

10.7326/aimcc.2022.0369 Get It

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
Kase, Adam M. , Azzouqa, Abdel‐Ghani, Kochuveettil, Swapna, Colón‐Otero, Gerardo

Mayo Clinic

Cancer Medicine | February 21, 2023 | Volume: 12 | Issue: 8 | Pages: 9434-9438

10.1002/cam4.5705 | PMID 36806695 Get It

AbstractBackgroundThe objective of this study was to evaluate the efficacy of gemcitabine plus nab‐paclitaxel in patients with recurrent ovarian cancer.MethodsWe performed a single institution retrospective review of patients with recurrent ovarian cancer who were treated with gemcitabine plus nab‐paclitaxel from 2012 to 2018 at the Mayo Clinic in Florida.ResultsTwenty patients were identified and the median PFS for patients treated with gemcitabine plus nab‐paclitaxel was 9 months (95% CI, 5.7–20.7). Overall, 17 of the 20 patients (85%) achieved a clinical benefit (complete response 5%, partial response 55%, or stable disease at 3 months 25%). For platinum‐sensitive disease and platinum‐resistant disease, the median OS were 38.7 months (95% CI, 5.8–63.1) and 31.2 months (95% CI, 12.8–51.8), respectively (p = 0.4306).ConclusionThis well‐tolerated regimen shows promising activity in recurrent ovarian cancer and is a viable option for patients who are intolerant to paclitaxel or carboplatin because of allergic reactions.
Survival of anterior cruciate ligament reconstructions in active‐duty military populations
Anderson, Ashley B. , Dekker, Travis J. , Pav, Veronika , Mauntel, Timothy C. , Provencher, Matthew T. , Tokish, John M. , Musahl, Volker , Sansone, Michael , Dickens, Jonathan F. , Dickens, Jonathan F , Extremity War Injury Symposium Working Group , Provencher, Matthew T. , Sansone, Michael, Karlsson, Jón

Mayo Clinic

Knee Surgery, Sports Traumatology, Arthroscopy | February 21, 2023 | Volume: 31 | Issue: 8 | Pages: 3196-3203

10.1007/s00167-023-07335-w | PMID 36809509 Get It

AbstractPurposeAnterior cruciate ligament tears and anterior cruciate ligament reconstruction (ACLR) are common in young athletes. The modifiable and non‐modifiable factors contributing to ACLR failure and reoperation are incompletely understood. The purpose of this study was to determine ACLR failure rates in a physically high‐demand population and identify the patient‐specific risk factors, including prolonged time between diagnosis and surgical correction, that portend failure.MethodsA consecutive series of military service members with ACLR with and without concomitant procedures (meniscus [M] and/or cartilage [C]) done at military facilities between 2008 and 2011 was completed via the Military Health System Data Repository. This was a consecutive series of patients without a history of knee surgery for two years prior to the primary ACLR. Kaplan–Meier survival curves were estimated and evaluated with Wilcoxon test. Cox proportional hazard models calculated hazard ratios (HR) with 95% confidence intervals (95% CI) to identify demographic and surgical factors that influenced ACLR failure.ResultsOf the 2735 primary ACLRs included in the study, 484/2,735 (18%) experienced ACLR failure within four years, including (261/2,735) (10%) undergoing revision ACLR and (224/2,735) (8%) due to medical separation. The factors that increased failure include Army Service (HR 2.19, 95% CI 1.67, 2.87), > 180 days from injury to ACLR (HR 1.550, 95% CI 1.157, 2.076), tobacco use (HR 1.429 95% CI 1.174, 1.738), and younger patient age (HR 1.024, 95% CI 1.004, 1.044).ConclusionThe overall clinical failure rate of service members with ACLR is 17.7% with minimum four‐year follow‐up, where more patients are likely to fail due to revision surgery than medical separation. The cumulative probability of survival at 4 years was 78.5%. Smoking cessation and treating ACLR patients promptly are modifiable risk factors impacting either graft failure or medical separation.Level of evidenceLevel III.
Out of View: A Large Esophageal Ulcer With Fistula to the Spine
Koop, Andree , Villalba, Michael , Hashash, Jana G.

Mayo Clinic

ACG Case Reports Journal | February 21, 2023 | Volume: 10 | Issue: 2 | Pages: e00883

10.14309/crj.0000000000000883 | PMID 36846358 Get It

Medical Parasitology Taxonomy Update, June 2020–June 2022
Mathison, Blaine A. , Bradbury, Richard S. , Pritt, Bobbi S. , Pritt, Bobbi S , Mathison, Blaine A

Mayo Clinic

Journal of Clinical Microbiology | February 21, 2023 | Volume: 61 | Issue: 5 | Pages: No page available

10.1128/jcm.00286-22 Get It

The taxonomy of medically important parasites continues to evolve. This minireview provides an update of additions and updates in the field of human parasitology from June 2020 through June 2022. A list of previously reported nomenclatural changes that have not been broadly adapted by the medical community is also included.
Undiagnosed obstructive sleep apnea increases risk of hospitalization among a racially diverse group of older adults with comorbid cardiovascular disease
Kirk, Jennifer , Somers, Virend K., Albrecht, Jennifer S. , Wickwire, Emerson M. , Somers, Virend K. , Johnson, Dayna A.

Mayo Clinic

Journal of Clinical Sleep Medicine | February 21, 2023 | Volume: 19 | Issue: 7 | Pages: 1175-1181

10.5664/jcsm.10526 | PMID 36803353 Get It

Peptide‐based formula: Clinical applications and benefits
Shah, Raj N. , Mundi, Manpreet S. , Mohamed Elfadil, Osman , Shah, Raj N , Hurt, Ryan T. , Mundi, Manpreet S , Elfadil, Osman Mohamed

Mayo Clinic

Nutrition in Clinical Practice | February 21, 2023 | Volume: 38 | Issue: 2 | Pages: 318-328

10.1002/ncp.10961 | PMID 36802281 Get It

Abstract The use of enteral nutrition (EN) continues to increase given benefits. However, with this increase in use, it is also becoming evident that enteral feeding intolerance (EFI) is also quite prevalent, leading to the inability to meet nutrition needs in many patients. Given the wide variability in the EN population as well as the number of formulas available, there is not a clear consensus regarding the best approach to EFI management. One approach that is emerging to improve EN tolerance is the use of peptide‐based formulas (PBFs). PBFs refer to enteral formulas containing proteins that have been enzymatically hydrolyzed to dipeptides and tripeptides. These hydrolyzed proteins are often combined with higher medium‐chain triglyceride content to generate an enteral formula that is essentially easier to absorb and utilize. Emerging data demonstrate that the use of PBF in patients with EFI may improve clinical outcomes along with a corresponding reduction in healthcare utilization and potentially the cost of care. This review aims to navigate through key clinical applications and benefits of PBF and to discuss relevant data shared in the literature.
Balamuthia mandrillaris Encephalitis Presenting as a Symptomatic Focal Hypodensity in an Immunocompromised Patient
Sakusic, Amra , McPhearson, Kimberly, Freeman, William D. , Huang, Josephine F. , Siegel, Jason , Jentoft, Mark E. , Oring, Justin , Verdecia, Jorge , Chen, Baibing , Freeman, William D , Siegel, Jason L, Oring, Justin M, Badi, Mohammed K. , Meschia, James F.

Mayo Clinic

Open Forum Infectious Diseases | February 21, 2023 | Volume: 10 | Issue: 3 | Pages: No page available

10.1093/ofid/ofad094 | PMID 37008568 Get It

Abstract We present the case of a 61-year-old woman with a history of orthotopic heart transplant who was hospitalized with new-onset headache. Magnetic resonance imaging (MRI) of the brain revealed T2 hyperintense signal involving the left occipital lobe with leptomeningeal enhancement and mild vasogenic edema. Initial neurologic examination was normal; however, after 7 days she developed imbalance, visual disturbances, night sweats, bradyphrenia, alexia without agraphia, and right hemianopsia. Brain MRI showed enlargement of the left occipital mass and worsening edema. Stereotactic needle biopsy showed nondiagnostic necrosis. The patient continued to deteriorate despite dexamethasone. Cerebrospinal fluid (CSF) suggested infection, and cytomegalovirus CSF polymerase chain reaction (PCR) was positive. The patient received vancomycin, imipenem, and ganciclovir. After obtaining a positive serum beta-D-glucan (Fungitell), amphotericin was added. Despite best medical efforts, the patient died. Postmortem broad-range PCR sequencing of the brain tissue was positive for rare amoeba Balamuthia mandrillaris.